Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 11 | 2025 | 179 | 1.990 |
Why?
|
| Breast Neoplasms | 14 | 2026 | 1723 | 1.800 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2025 | 12 | 1.780 |
Why?
|
| Mastectomy, Segmental | 4 | 2022 | 25 | 1.260 |
Why?
|
| Diabetes Mellitus | 2 | 2025 | 539 | 1.090 |
Why?
|
| Biomedical Technology | 1 | 2025 | 12 | 0.940 |
Why?
|
| Medical Oncology | 1 | 2025 | 50 | 0.920 |
Why?
|
| Medically Underserved Area | 1 | 2025 | 120 | 0.830 |
Why?
|
| Prediabetic State | 1 | 2025 | 69 | 0.820 |
Why?
|
| Cardiovascular Diseases | 3 | 2025 | 749 | 0.780 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 310 | 0.720 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 78 | 0.700 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 247 | 0.660 |
Why?
|
| Heart Failure | 1 | 2023 | 302 | 0.610 |
Why?
|
| Stroke | 1 | 2023 | 340 | 0.600 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 47 | 0.560 |
Why?
|
| Aged | 15 | 2026 | 8214 | 0.530 |
Why?
|
| Humans | 32 | 2026 | 43102 | 0.480 |
Why?
|
| United States | 10 | 2026 | 5205 | 0.470 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 1019 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 760 | 0.450 |
Why?
|
| Neoplasms | 1 | 2025 | 1377 | 0.430 |
Why?
|
| Insurance, Health | 2 | 2014 | 145 | 0.420 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2022 | 75 | 0.400 |
Why?
|
| Female | 18 | 2026 | 24698 | 0.390 |
Why?
|
| Retrospective Studies | 5 | 2026 | 2544 | 0.380 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 512 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 220 | 0.360 |
Why?
|
| Models, Economic | 2 | 2024 | 28 | 0.330 |
Why?
|
| Prostatic Neoplasms | 6 | 2015 | 1092 | 0.320 |
Why?
|
| Medicare | 2 | 2022 | 332 | 0.300 |
Why?
|
| Middle Aged | 13 | 2025 | 12222 | 0.290 |
Why?
|
| Aged, 80 and over | 5 | 2026 | 2853 | 0.240 |
Why?
|
| Florida | 7 | 2015 | 478 | 0.230 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 173 | 0.230 |
Why?
|
| Adult | 12 | 2025 | 13872 | 0.220 |
Why?
|
| Hospitalization | 2 | 2025 | 485 | 0.220 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 237 | 0.220 |
Why?
|
| Health Care Sector | 1 | 2024 | 10 | 0.210 |
Why?
|
| Survival Analysis | 3 | 2023 | 368 | 0.210 |
Why?
|
| Patient Readmission | 1 | 2025 | 122 | 0.210 |
Why?
|
| Registries | 4 | 2014 | 437 | 0.210 |
Why?
|
| Liver Transplantation | 1 | 2023 | 37 | 0.200 |
Why?
|
| Tissue and Organ Procurement | 1 | 2023 | 54 | 0.190 |
Why?
|
| Fatty Liver | 1 | 2023 | 77 | 0.190 |
Why?
|
| Myocardial Ischemia | 1 | 2023 | 83 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 497 | 0.190 |
Why?
|
| Glucosides | 1 | 2022 | 21 | 0.180 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 163 | 0.180 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 50 | 0.180 |
Why?
|
| Risk Factors | 3 | 2025 | 3994 | 0.180 |
Why?
|
| Male | 10 | 2025 | 23409 | 0.170 |
Why?
|
| Logistic Models | 4 | 2023 | 1009 | 0.170 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 116 | 0.170 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 195 | 0.170 |
Why?
|
| Mastectomy | 2 | 2026 | 21 | 0.170 |
Why?
|
| Survival Rate | 1 | 2020 | 355 | 0.160 |
Why?
|
| Piperazines | 1 | 2020 | 120 | 0.150 |
Why?
|
| Pyridines | 1 | 2020 | 139 | 0.150 |
Why?
|
| Decision Making | 1 | 2021 | 249 | 0.150 |
Why?
|
| Depression | 1 | 2026 | 863 | 0.140 |
Why?
|
| Delayed Diagnosis | 2 | 2014 | 38 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 24 | 0.130 |
Why?
|
| Propensity Score | 1 | 2016 | 59 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 49 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2018 | 1604 | 0.130 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 449 | 0.120 |
Why?
|
| Quality of Life | 1 | 2019 | 616 | 0.110 |
Why?
|
| Thiocarbamates | 1 | 2014 | 5 | 0.110 |
Why?
|
| Androstadienes | 1 | 2014 | 19 | 0.110 |
Why?
|
| Antineoplastic Protocols | 1 | 2013 | 1 | 0.100 |
Why?
|
| Data Collection | 1 | 2013 | 210 | 0.090 |
Why?
|
| Adolescent | 1 | 2023 | 6081 | 0.090 |
Why?
|
| Comorbidity | 4 | 2014 | 737 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1234 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 375 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 590 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2015 | 341 | 0.070 |
Why?
|
| Markov Chains | 2 | 2019 | 43 | 0.070 |
Why?
|
| Mass Screening | 2 | 2023 | 541 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2013 | 502 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 3156 | 0.070 |
Why?
|
| SEER Program | 1 | 2026 | 164 | 0.060 |
Why?
|
| Multilevel Analysis | 2 | 2015 | 21 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2023 | 989 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 374 | 0.050 |
Why?
|
| Health Surveys | 1 | 2025 | 405 | 0.050 |
Why?
|
| Living Donors | 1 | 2023 | 18 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2023 | 38 | 0.050 |
Why?
|
| Graft Survival | 1 | 2023 | 47 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 53 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 278 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2025 | 863 | 0.050 |
Why?
|
| Patient Preference | 1 | 2021 | 60 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2021 | 93 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2023 | 338 | 0.040 |
Why?
|
| Age Factors | 2 | 2013 | 1154 | 0.040 |
Why?
|
| Taiwan | 1 | 2019 | 23 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 53 | 0.040 |
Why?
|
| Nitriles | 1 | 2019 | 81 | 0.040 |
Why?
|
| Postmenopause | 1 | 2019 | 141 | 0.040 |
Why?
|
| Focus Groups | 1 | 2021 | 423 | 0.040 |
Why?
|
| Triazoles | 1 | 2019 | 102 | 0.040 |
Why?
|
| Hypertension | 1 | 2025 | 835 | 0.040 |
Why?
|
| Maytansine | 1 | 2017 | 2 | 0.030 |
Why?
|
| Public Health | 1 | 2022 | 424 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 50 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 17 | 0.030 |
Why?
|
| Health Resources | 1 | 2016 | 37 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 690 | 0.030 |
Why?
|
| Mexico | 1 | 2017 | 298 | 0.030 |
Why?
|
| Probability | 1 | 2016 | 82 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 91 | 0.030 |
Why?
|
| Marital Status | 1 | 2014 | 46 | 0.030 |
Why?
|
| Single Person | 1 | 2013 | 6 | 0.030 |
Why?
|
| Sirolimus | 1 | 2014 | 70 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 92 | 0.030 |
Why?
|
| Poverty Areas | 1 | 2013 | 47 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2013 | 65 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 68 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 667 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 12 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 183 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 27 | 0.020 |
Why?
|
| Hospitals | 1 | 2013 | 117 | 0.020 |
Why?
|
| Life Style | 1 | 2014 | 334 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 249 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 719 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1078 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2014 | 719 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 1024 | 0.020 |
Why?
|